The Undiagnosed Diseases Network (UDN), a clinical research initiative of the National Institutes of Health (NIH), has opened an online patient application portal called the UDN Gateway. Introduction of this application system sets the stage for the network to advance its core mission: to diagnose patients who suffer from conditions that even skilled physicians have been unable to diagnose despite extensive clinical investigation.
Associate Editor MHT- Boston Business Journal
The U.S. Food and Drug Administration has accepted the second of the two applications for a biologic drug candidate to treat hemophilia that Biogen Idec. (Nasdaq:BIIB) has submitted this year.
Shire plc, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an orphan medicine through the Centralised Procedure, making it available in 30 countries across Europe.
By PAULINE ANDERSON
Although the effect is small, quinine derivatives can be useful in treating muscle cramps but should not be used routinely because of potential toxic effects, a new evidence-based review of the literature has concluded.
Quinine, which is also indicated for the treatment of Plasmodium falciparum malaria, should only be considered to treat muscle cramps when the cramps are disabling, when other agents have failed to relieve symptoms, and after patients have been informed of potentially serious adverse effects, the reviewers conclude in their assessment.